Literature DB >> 15919646

Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention.

R V Kelly1, S Steinhubl.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15919646      PMCID： PMC1876353          DOI： 10.1136/hrt.2004.058511

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  26 in total

1.  Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.

Authors:  Marco Roffi; Debabrata Mukherjee; Derek P Chew; Deepak L Bhatt; Leslie Cho; Mark A Robbins; Khaled M Ziada; Danielle M Brennan; Stephen G Ellis; Eric J Topol
Journal:  Circulation       Date:  2002-12-10       Impact factor: 29.690

Review 2.  Scientific and therapeutic advances in antiplatelet therapy.

Authors:  Deepak L Bhatt; Eric J Topol
Journal:  Nat Rev Drug Discov       Date:  2003-01       Impact factor: 84.694

3.  A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention.

Authors:  Rémi Choussat; Gilles Montalescot; Jean Philippe Collet; Eric Vicaut; Annick Ankri; Vanessa Gallois; Gérard Drobinski; Ivan Sotirov; Daniel Thomas
Journal:  J Am Coll Cardiol       Date:  2002-12-04       Impact factor: 24.094

4.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Authors:  A Michael Lincoff; John A Bittl; Robert A Harrington; Frederick Feit; Neal S Kleiman; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Dean J Kereiakes; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

Review 5.  A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes.

Authors:  Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2003-02-19       Impact factor: 24.094

6.  Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.

Authors:  Evangelia Karvouni; Demosthenes G Katritsis; John P A Ioannidis
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

7.  Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.

Authors:  James J Ferguson; Elliott M Antman; Eric R Bates; Marc Cohen; Nathan R Every; Robert A Harrington; Carl J Pepine; Pierre Theroux
Journal:  Am Heart J       Date:  2003-10       Impact factor: 4.749

8.  A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.

Authors:  Adnan Kastrati; Julinda Mehilli; Helmut Schühlen; Josef Dirschinger; Franz Dotzer; Jurriën M ten Berg; Franz-Josef Neumann; Hildegard Bollwein; Christian Volmer; Meinrad Gawaz; Peter B Berger; Albert Schömig
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

9.  Extension of increased atherosclerotic wall thickness into high shear stress regions is associated with loss of compensatory remodeling.

Authors:  Jolanda J Wentzel; Elbert Janssen; Jeroen Vos; Johan C H Schuurbiers; Rob Krams; Patrick W Serruys; Pim J de Feyter; Cornelis J Slager
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

Review 10.  What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?

Authors:  Steven Steinhubl; Peter Berger
Journal:  Am Heart J       Date:  2003-06       Impact factor: 4.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.